Paris, France

Michèle Rosenzwajg

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 6.4

ph-index = 2

Forward Citations = 13(Granted Patents)


Company Filing History:


Years Active: 2017-2023

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Michèle Rosenzwajg: Innovator in Autoimmune and Inflammatory Disease Treatments

Introduction

Michèle Rosenzwajg is a prominent inventor based in Paris, France. He has made significant contributions to the field of medicine, particularly in the treatment of autoimmune and inflammatory disorders. With a total of four patents to his name, Rosenzwajg's work is paving the way for novel therapeutic approaches.

Latest Patents

One of his latest patents focuses on the use of low-dose interleukin-2 for treating autoimmune-related or inflammatory disorders. This invention specifically addresses the treatment of type I diabetes and other autoimmune and inflammatory diseases. Another notable patent involves the use of interleukin-2 for treating Sjögren's syndrome, where IL-2 is administered at a low dose of less than about 3.5 MIU/day. These innovations highlight his commitment to advancing medical treatments.

Career Highlights

Throughout his career, Michèle Rosenzwajg has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and Assistance Publique-Hôpitaux de Paris. His experience in these organizations has allowed him to develop and refine his groundbreaking ideas in the medical field.

Collaborations

Rosenzwajg has collaborated with notable professionals, including David Klatzmann and Patrice Cacoub. These partnerships have further enriched his research and contributed to the success of his inventions.

Conclusion

In summary, Michèle Rosenzwajg is a distinguished inventor whose work in autoimmune and inflammatory disease treatments is making a significant impact. His innovative patents and collaborations reflect his dedication to improving patient outcomes through advanced medical therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…